Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01759355
Other study ID # LCCC1221
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 2012
Est. completion date May 28, 2020

Study information

Verified date December 2021
Source UNC Lineberger Comprehensive Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a two arm, single center feasibility study of 20 patients with non-metastatic cervical cancer managed with surgery and/or chemoradiation therapy at UNC Hospitals. Subjects will undergo PET/MRI scans before, during (chemoradiation group only), and after treatment.


Description:

The primary purpose of this study is to evaluate the feasibility of obtaining complete and interpretable hybrid PET/MR images for patients diagnosed with cervical cancer.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date May 28, 2020
Est. primary completion date May 28, 2020
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - = 18 years of age - Biopsy-proven, previously untreated squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the uterine cervix - Clinically visible lesion at least FIGO stage Ib or AJCC 7th edition T1b - Scheduled to undergo standard of care PET/CT for baseline assessment of disease - Anticipated to be eligible for curative intent therapy (surgery of chemoradiation therapy) as determined by the patient's primary oncologist - If female of child-bearing potential, negative serum or urine pregnancy test = 7 dats prior to first PET/MRI - Informed consent reviewed and signed Exclusion Criteria: - History of sever reaction to contrast-enhanced CT scan - Inability to tolerate MRI (e.g., inability to lie flat > 1 hour) - Presence of pacemaker, intracranial aneurysm clip, bladder stimulator, cochlear implant or metal near eyes - Poorly controlled diabetes mellitus - Creatinine > 1.4 mg/dL or GFR < 30 mL/min - Body Mass Index (BMI) > 35 - Active vaginal bleeding requiring packing and emergent radiation therapy - Pregnant or lactating female - History of a prior malignancy within past 5 years, unless disease free for = 3 years - Substance abuse, medical, psychological, or social conditions that may interfere with study participation

Study Design


Intervention

Procedure:
FDG PET/MR
Participants will undergo a FDG, gadolinium enhanced PET/MR scan.

Locations

Country Name City State
United States University of North Carolina-Chapel Hill Chapel Hill North Carolina

Sponsors (1)

Lead Sponsor Collaborator
UNC Lineberger Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients who successfully complete PET/MR scans at all study time-points 2-3 months post-treatment
Secondary Sensitivity of PET/MR for baseline disease assessment Estimated proportion of subjects with disease (positive pathology or PET/CT) that have positive PET/MR scans. pre-treatment
Secondary Specificity of hybrid PET/MR for baseline disease assessment Proportion of subjects without disease (negative pathology or PET/CT) that have negative PET/MR scans. pre-treatment
Secondary Accuracy of hybrid PET/MR for baseline disease assessment Proportion of correct assessments among total population pre-treatment
Secondary Detection of disease with PET/MR at each time point pre-treatment to 2-3 months post-treatment
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05013268 - Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma Phase 1
Completed NCT02562729 - Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer Phase 2
Completed NCT00416455 - Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Phase 1/Phase 2
Completed NCT00054444 - Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer Phase 1
Recruiting NCT05210348 - Clinical Evaluation of Detection of High Risk HPV in Urine
Completed NCT00068549 - Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer Phase 1
Active, not recruiting NCT03983954 - Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors Phase 1
Completed NCT00559377 - FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer Phase 2
Completed NCT00309959 - ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Active, not recruiting NCT05613283 - Primary Cervical Cancer Screening by Self-sampling HPV Test
Completed NCT00064077 - Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Phase 3
Active, not recruiting NCT02466971 - Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers Phase 3
Completed NCT02164461 - Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer Phase 1
Completed NCT01807546 - Oral Rigosertib for Squamous Cell Carcinoma Phase 2
Completed NCT00031993 - Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix Phase 2
Active, not recruiting NCT01649089 - Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer N/A
Completed NCT00499031 - Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Terminated NCT00070317 - Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer N/A
Not yet recruiting NCT04976478 - Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma
Active, not recruiting NCT03738228 - Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer Phase 1